Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis

Mevalonate metabolism in cancer

(2015) Georg Gruenbacher et al.   CANCER LETTERS

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate

(2015) Mohammed Al-Bogami et al.   SAUDI MEDICAL JOURNAL

Estimating prevalence of osteoporosis: examples from industrialized countries

(2014) S. W. Wade et al.   Archives of Osteoporosis

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A reappraisal of generic bisphosphonates in osteoporosis

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis

(2010) Jawl-Shan Hwang et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Long-Term Use of Bisphosphonates in Osteoporosis

(2010) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women

(2008) Andrew Grey et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

(2008) R. G. G. Russell et al.   OSTEOPOROSIS INTERNATIONAL